How do I install the Endo T Generalized Use Against skill?

Run npx skillmds@latest add dromlakhani/endo-t-generalized-use-against in your terminal (requires Node.js), paste this page's agent-chat prompt into Claude, Cursor, or any MCP-connected agent, or download the SKILL.md file and copy it into your agent's skills directory.

Is Endo T Generalized Use Against safe to use?

This skill has not completed SkillMD's automated safety review yet. Independent scanners report: SkillSpector: PASS, Skill Scanner: PASS. Capability flags: docs only. SkillMD never runs a skill's scripts for you; review the SKILL.md before installing.

Which AI agents work with Endo T Generalized Use Against?

This skill is tagged as working with Claude Code, Claude.ai, OpenAI Codex. SKILL.md is an open format, so most agents that read a skills directory can load it too.

Is Endo T Generalized Use Against free to use?

Yes. Installing skills from SkillMD is free, and the skill stays under its author's original license.

Who published Endo T Generalized Use Against?

dromlakhani (@dromlakhani) published this skill. Their other Agent Skills are listed on their SkillMD profile.

Endo T Generalized Use Against by dromlakhani

Name: Endo T Generalized Use Against
Rating: 4.2 (5 reviews)
Author: dromlakhani

Endo T Generalized Use Against

The guideline recommends against generalized testosterone use for indications such as infertility, sexual dysfunction other than HSDD, cognitive, cardiovascular, metabolic, bone health, or general well-being due to insufficient evidence of benefit and lacking long-term safety data. Consider this recommendation when a clinician contemplates prescribing testosterone for any indication other than confirmed hypoactive sexual desire disorder in postmenopausal women.

dromlakhani Updated Sep 8, 2026 10 repo stars

File contents

Recommend against generalized testosterone use for non-HSDD indications

STEP 1 — Gather Information

Collect the specific indication for testosterone request, confirm menopausal status, and determine whether a diagnosis of hypoactive sexual desire disorder (HSDD) has been established.
Action: Proceed to step 2.

STEP 2 — Rule In / Rule Out

Determine if the indication is HSDD in a postmenopausal woman.
Action: If yes, testosterone may be considered per recommendation 4.1 (outside this skill); if no, proceed to step 3.

STEP 3 — Classify or Stratify

Classify the non-HSDD indication into one of the following categories: infertility, sexual dysfunction other than HSDD, cognitive dysfunction, cardiovascular dysfunction, metabolic dysfunction, bone health, or general well-being.
Action: Proceed to step 4.

STEP 4 — Decide

Recommend against prescribing testosterone for the given indication due to lack of clear indications and insufficient long-term safety data.
Action: Do not initiate testosterone therapy; discuss alternative approaches.

Clinical Guardrails / Mimics / Pitfalls

Do not prescribe testosterone for non-HSDD indications based on low androgen levels alone; avoid unapproved or compounded formulations lacking safety data; do not use testosterone to treat fatigue, mood, or cognitive symptoms without an HSDD diagnosis; monitor for signs of androgen excess (acne, hirsutism, voice changes) if testosterone is used off-label; recognize that government‑approved dose‑appropriate preparations for women are not widely available.

Concrete Clinical Example

A 58‑year‑old postmenopausal woman presents with low energy and decreased libido but does not meet criteria for HSDD. She requests testosterone for “vitality.” The clinician gathers information, confirms the indication is not HSDD, classifies it as general well‑being, and recommends against testosterone, discussing lifestyle modifications and evaluating for other causes of fatigue.

Source: Androgen Therapy in Women: A Reappraisal: An Endocrine Society Clinical Practice Guideline, Endocrine Society, American Congress of Obstetricians and Gynecologists (ACOG), American Society for Reproductive Medicine (ASRM), European Society of Endocrinology (ESE), International Menopause Society (IMS), 2014, DOI:10.1210/jc.2014-2260

---name: endo-t-generalized-use-againstdescription: The guideline recommends against generalized testosterone use for indications such as infertility, sexual dysfunction other than HSDD, cognitive, cardiovascular, metabolic, bone health, or general well-being due to insufficient evidence of benefit and lacking long-term safety data. Consider this recommendation when a clinician contemplates prescribing testosterone for any indication other than confirmed hypoactive sexual desire disorder in postmenopausal women.---# Recommend against generalized testosterone use for non-HSDD indications## STEP 1 — Gather InformationCollect the specific indication for testosterone request, confirm menopausal status, and determine whether a diagnosis of hypoactive sexual desire disorder (HSDD) has been established. **Action:** Proceed to step 2.## STEP 2 — Rule In / Rule OutDetermine if the indication is HSDD in a postmenopausal woman. **Action:** If yes, testosterone may be considered per recommendation 4.1 (outside this skill); if no, proceed to step 3.## STEP 3 — Classify or StratifyClassify the non-HSDD indication into one of the following categories: infertility, sexual dysfunction other than HSDD, cognitive dysfunction, cardiovascular dysfunction, metabolic dysfunction, bone health, or general well-being. **Action:** Proceed to step 4.## STEP 4 — DecideRecommend against prescribing testosterone for the given indication due to lack of clear indications and insufficient long-term safety data. **Action:** Do not initiate testosterone therapy; discuss alternative approaches.## Clinical Guardrails / Mimics / PitfallsDo not prescribe testosterone for non-HSDD indications based on low androgen levels alone; avoid unapproved or compounded formulations lacking safety data; do not use testosterone to treat fatigue, mood, or cognitive symptoms without an HSDD diagnosis; monitor for signs of androgen excess (acne, hirsutism, voice changes) if testosterone is used off-label; recognize that government‑approved dose‑appropriate preparations for women are not widely available.## Concrete Clinical ExampleA 58‑year‑old postmenopausal woman presents with low energy and decreased libido but does not meet criteria for HSDD. She requests testosterone for “vitality.” The clinician gathers information, confirms the indication is not HSDD, classifies it as general well‑being, and recommends against testosterone, discussing lifestyle modifications and evaluating for other causes of fatigue.**Source:** Androgen Therapy in Women: A Reappraisal: An Endocrine Society Clinical Practice Guideline, Endocrine Society, American Congress of Obstetricians and Gynecologists (ACOG), American Society for Reproductive Medicine (ASRM), European Society of Endocrinology (ESE), International Menopause Society (IMS), 2014, DOI:10.1210/jc.2014-2260

Frequently asked questions